{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:25:13Z","timestamp":1778253913039,"version":"3.51.4"},"reference-count":54,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kazia Therapeutics Pty Ltd","award":["NVGV 002-101"],"award-info":[{"award-number":["NVGV 002-101"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Survival outcomes in ovarian cancer are poor. The aims of this Phase I progressive design study (NCT02903771) were to evaluate the maximum tolerated dose (MTD), tolerability, and antitumor activity of Cantrixil\u2014a novel third-generation benzopyran molecule\u2014in patients (n = 25) with advanced, recurrent\/persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer. All had completed \u2265 2 prior regimens; 3 (12%) had platinum-refractory disease, and 17 (68%) had platinum-resistant disease. Following intraperitoneal (IP) port placement, patients received weekly IP Cantrixil in 3-week cycles as monotherapy (Cycles 1\u20132), and then in combination with intravenous (IV) chemotherapy (Cycles 3\u20138). Part A (dose escalation) enrolled 11 patients in 6 dose-level cohorts. An MTD of 5 mg\/kg was established with dose-limiting toxicity of ileus. Most treatment-related adverse events were gastrointestinal. Across Parts A and B (dose expansion), 16 (64%) patients received \u2265 1 3-week Cantrixil cycle, and had \u2265 1 post-baseline efficacy measurement available. The results show promising anti-tumor activity in monotherapy (stable disease rate of 56%) and in combination with IV chemotherapy (objective response rate of 19%, disease control rate of 56%, and median progression-free survival of 13.1 weeks). The molecular target and mechanism of action of Cantrixil are yet to be confirmed. Preliminary analysis of stem cell markers suggests that IP Cantrixil might induce ovarian cancer stem cell death and sensitize cells to standard chemotherapy, warranting further evaluation.<\/jats:p>","DOI":"10.3390\/cancers13133196","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T22:24:57Z","timestamp":1624832697000},"page":"3196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-9379","authenticated-orcid":false,"given":"Jermaine I.","family":"Coward","sequence":"first","affiliation":[{"name":"ICON Cancer Centre, South Brisbane, QLD 4101, Australia"},{"name":"School of Medicine, University of Queensland, Brisbane, QLD 4072, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minal A.","family":"Barve","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research Center, Dallas, TX 75251, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5149","authenticated-orcid":false,"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre, Adelaide, SA 5042, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, OK 73104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Harnett","sequence":"additional","affiliation":[{"name":"Crown Princess Mary Cancer Centre, Westmead, NSW 2145, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Berg","sequence":"additional","affiliation":[{"name":"Formerly of Kazia Therapeutics Ltd., Sydney, NSW 2000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Garner","sequence":"additional","affiliation":[{"name":"Kazia Therapeutics Ltd., Sydney, NSW 2000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[{"name":"Lifespan Cancer Institute, Providence, RI 02913, USA"},{"name":"The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin.","DOI":"10.3322\/caac.21660"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ijgo.2015.06.007","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"131","author":"Berek","year":"2015","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41416-019-0718-9","article-title":"Improved early detection of ovarian cancer using longitudinal multimarker models","volume":"122","author":"Whitwell","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: Standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00228-020-02874-4","article-title":"A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients","volume":"76","author":"Watson","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_7","first-page":"1758835918768232","article-title":"First-line treatment of ovarian cancer: Questions and controversies to address","volume":"10","author":"Ledermann","year":"2018","journal-title":"Adv. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2008.09.010","article-title":"Stage IV ovarian cancer: Disease site-specific rationale for postoperative treatment","volume":"112","author":"Aletti","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s10147-020-01714-w","article-title":"Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence","volume":"25","author":"Tate","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ygyno.2020.03.003","article-title":"Prognostic value of radiological recurrence patterns in ovarian cancer","volume":"157","author":"Roze","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1002\/cam4.1631","article-title":"A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer","volume":"7","author":"Sarkar","year":"2018","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Latifi, A., Luwor, R.B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E.W., Quinn, M.A., and Findlay, J.K. (2012). Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: Molecular phenotype of chemoresistant ovarian tumors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046858"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem Cells cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-017-0644-8","article-title":"Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2","volume":"36","author":"Peng","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/21678707.2018.1508339","article-title":"The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer","volume":"6","author":"Saif","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"1021","article-title":"How to win the ovarian cancer stem cell battle: Destroying the roots","volume":"4","author":"Takahashi","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/IGC.0b013e3182126f05","article-title":"Phase II Evaluation of Phenoxodiol in Combination with Cisplatin or Paclitaxel in Women with Platinum\/Taxane-Refractory\/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers","volume":"21","author":"Kelly","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656560902837980","article-title":"Phenoxodiol: Pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs","volume":"10","author":"Silasi","year":"2009","journal-title":"Expert Opin. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1038\/s41598-018-22882-w","article-title":"Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo","volume":"8","author":"Stevenson","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-16-0005","article-title":"TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo","volume":"15","author":"Alvero","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2014184","DOI":"10.1001\/jamanetworkopen.2020.14184","article-title":"Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?","volume":"3","author":"Alter","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1158\/0008-5472.CAN-15-1620","article-title":"Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer","volume":"76","author":"Winner","year":"2016","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00280-016-3224-2","article-title":"Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)","volume":"79","author":"Saif","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","unstructured":"Hoskins, P.J. (2006). Intraperitoneal Therapy for British Columbia, BC Cancer Agency Gynecological Tumour Group. Available online: http:\/\/www.bccancer.bc.ca\/books\/Documents\/Gynecology\/GyneovaryIntraperitonealChemotherapyforBC_June06.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/IJWH.S52379","article-title":"New perspectives on targeted therapy in ovarian cancer","volume":"7","author":"Coward","year":"2015","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_35","first-page":"292","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: Results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Med. Oncol. (NorthwoodLond. Engl.)"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"Elsaid","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","article-title":"Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer","volume":"111","author":"Hamilton","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chen, W.C., Qiu, J.T., Lai, C.H., Huang, H.J., Lin, C.T., Chen, M.Y., Chou, H.H., Huang, K.G., and Chang, T.C. (2017). Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175703"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","volume":"161","author":"Sjoquist","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10637-009-9351-4","article-title":"Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review","volume":"28","author":"Bellati","year":"2010","journal-title":"Invest. New Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I.G., Rahimi, H., Gasparri, M.L., Antonilli, M., Panici, P.B., Rughetti, A., and Nuti, M. (2019). Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030380"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1078-0432.CCR-08-2081","article-title":"Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1","volume":"15","author":"Jandial","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2017.03.013","article-title":"A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Jandial","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/0008-5472.CAN-11-0814","article-title":"Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells","volume":"71","author":"Huehls","year":"2011","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Muggia, F., and Bonetti, A. (2021). History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications. Cancer Drug Resist., 4.","DOI":"10.20517\/cdr.2020.116"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., Wang, X., Huss, W.J., Lele, S.B., and Morrison, C.D. (2014). Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084941"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13048-020-00618-7","article-title":"Integrative analysis of transcription factors and microRNAs in ovarian cancer cell spheroids","volume":"13","author":"Park","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Galv\u00e1n, S., and Carnero, A. (2020). Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 9.","DOI":"10.3390\/cells9061402"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3904645","DOI":"10.1155\/2019\/3904645","article-title":"Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells","volume":"2019","author":"Vassalli","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1158\/1535-7163.MCT-10-0563","article-title":"Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer","volume":"9","author":"Landen","year":"2010","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:45Z","timestamp":1760163885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":54,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13133196"],"URL":"https:\/\/doi.org\/10.3390\/cancers13133196","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]}}}